In the article “Both cladribine and alemtuzumab may effect MS via B-cell depletion” by D. Baker et al.,1 the title should read “Both cladribine and alemtuzumab may affect MS via B-cell depletion.” The authors regret the error. Additionally, in the key for figure 2 the red diamond should indicate “CLAD 3.5 mg/kg” rather than “CLAD 6.5 mg/kg” as originally published. The editorial staff regret the error.
- © 2017 American Academy of Neurology
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
